Cutaneous melanoma
Alexander M.M. Eggermont, Alan Spatz, Caroline Robert · The Lancet · 2013
Cited by 548 works. doi:10.1016/s0140-6736(13)60802-8
Authors
References
- Cancer Incidence in Five Continents
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Mutations of the BRAF gene in human cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma